These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 18403055)
1. CSF biomarker levels in early and late onset Alzheimer's disease. Bouwman FH; Schoonenboom NS; Verwey NA; van Elk EJ; Kok A; Blankenstein MA; Scheltens P; van der Flier WM Neurobiol Aging; 2009 Dec; 30(12):1895-901. PubMed ID: 18403055 [TBL] [Abstract][Full Text] [Related]
2. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251 [TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554 [TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538 [TBL] [Abstract][Full Text] [Related]
6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432 [TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456 [TBL] [Abstract][Full Text] [Related]
8. CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Schoonenboom NS; van der Flier WM; Blankenstein MA; Bouwman FH; Van Kamp GJ; Barkhof F; Scheltens P Neurobiol Aging; 2008 May; 29(5):669-75. PubMed ID: 17208336 [TBL] [Abstract][Full Text] [Related]
9. Longitudinal changes of CSF biomarkers in memory clinic patients. Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669 [TBL] [Abstract][Full Text] [Related]
10. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559 [TBL] [Abstract][Full Text] [Related]
11. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Blennow K; Zetterberg H; Minthon L; Lannfelt L; Strid S; Annas P; Basun H; Andreasen N Neurosci Lett; 2007 May; 419(1):18-22. PubMed ID: 17482358 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
14. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease. Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066 [TBL] [Abstract][Full Text] [Related]
15. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530 [TBL] [Abstract][Full Text] [Related]
16. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Lewczuk P; Kornhuber J; Vanderstichele H; Vanmechelen E; Esselmann H; Bibl M; Wolf S; Otto M; Reulbach U; Kölsch H; Jessen F; Schröder J; Schönknecht P; Hampel H; Peters O; Weimer E; Perneczky R; Jahn H; Luckhaus C; Lamla U; Supprian T; Maler JM; Wiltfang J Neurobiol Aging; 2008 Jun; 29(6):812-8. PubMed ID: 17239996 [TBL] [Abstract][Full Text] [Related]
17. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Ibach B; Binder H; Dragon M; Poljansky S; Haen E; Schmitz E; Koch H; Putzhammer A; Kluenemann H; Wieland W; Hajak G Neurobiol Aging; 2006 Sep; 27(9):1202-11. PubMed ID: 16085339 [TBL] [Abstract][Full Text] [Related]
19. Increase in beta-amyloid levels in cerebrospinal fluid of children with Down syndrome. Englund H; Annerén G; Gustafsson J; Wester U; Wiltfang J; Lannfelt L; Blennow K; Höglund K Dement Geriatr Cogn Disord; 2007; 24(5):369-74. PubMed ID: 17914261 [TBL] [Abstract][Full Text] [Related]